Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?()

BACKGROUND: Chronic Spontaneous Urticaria (CSU) is characterized by recurrent wheals and/or angioedema for longer than 6-weeks. Guidelines recommend Omalizumab (Oma) as first-line and Cyclosporine-A (Cs-A) as second-line treatment in antihistamine resistant CSU. This step-wise algorithm might be tim...

Descripción completa

Detalles Bibliográficos
Autores principales: Kocatürk, Emek, Başkan, Emel Bülbül, Küçük, Özlem Su, Özdemir, Mustafa, Örnek, Sinem, Can, Pelin Kuteyla, Haşal, Eda, Engin, Burhan, Atakan, Nilgün, Alpsoy, Erkan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Dermatologia 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453514/
https://www.ncbi.nlm.nih.gov/pubmed/35853771
http://dx.doi.org/10.1016/j.abd.2022.03.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453514/
https://www.ncbi.nlm.nih.gov/pubmed/35853771
http://dx.doi.org/10.1016/j.abd.2022.03.003

Ejemplares similares